Delayed obsessive compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients

被引:29
作者
Greenberg, DB [1 ]
Benjamin, J [1 ]
Martin, JD [1 ]
Keuler, D [1 ]
Huang, SJ [1 ]
Altemus, M [1 ]
Murphy, DL [1 ]
机构
[1] NIMH, Clin Sci Lab, Bethesda, MD 20892 USA
关键词
obsessive-compulsive disorder; anxiety; serotonin reuptake inhibitor; serotonin antagonist; metergoline; fluoxetine;
D O I
10.1007/s002130050787
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Enhanced serotonergic transmission may underlie therapeutic effects of serotonin reuptake inhibitors in obsessive-compulsive disorder. However, such treatment may decrease serotonin receptor responsivity. We investigated whether the serotonin antagonist metergoline would exacerbate or further improve systems in fluoxetine-responsive patients. Pilot results suggested open metergoline produced delayed symptom worsening in fluoxetine-treated patients. Fourteen patients continuing fluoxetine received metergoline and placebo (double-blind, randomized). Symptom ratings continued for 1 week afterwards. Ten unmedicated patients underwent the same procedures. Symptoms improved 4 h after both metergoline and placebo. The day after metergoline but not placebo, fluoxetine-treated patients had significantly increased anxiety, obsessions and compulsions, abating over several days. Depression was unchanged. Metergoline had no similar delayed effects in unmedicated patients. Metergoline levels were higher in fluoxetine-treated patients. These results, consistent with less conclusive earlier findings, suggest that prolonged changes in brain serotonin function underlie symptom re-emergence following administration of metergoline to fluoxetine-treated patients with obsessive-compulsive disorder.
引用
收藏
页码:434 / 444
页数:11
相关论文
共 45 条
[1]  
BARR LC, 1994, ARCH GEN PSYCHIAT, V51, P309
[2]   Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects [J].
Benjamin, J ;
Greenberg, BD ;
Murphy, DL .
PSYCHOPHARMACOLOGY, 1996, 127 (02) :140-149
[3]  
BENKELFAT C, 1989, ARCH GEN PSYCHIAT, V46, P23
[4]  
BERETTA C, 1965, NATURE, V205, P421
[5]   CURRENT ADVANCES AND TRENDS IN THE TREATMENT OF DEPRESSION [J].
BLIER, P ;
DEMONTIGNY, C .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) :220-226
[6]  
DELGADO PL, 1990, ARCH GEN PSYCHIAT, V47, P411
[7]  
DELGADO PL, 1988, ABSTR SOC NEUROSCI, V14, P970
[8]  
DENNIS T, 1993, J PSYCHIATR NEUROSCI, V18, P264
[9]   MOLECULAR PSYCHIATRY - ADAPTATIONS OF RECEPTOR-COUPLED SIGNAL-TRANSDUCTION PATHWAYS UNDERLYING STRESS-INDUCED AND DRUG-INDUCED NEURAL PLASTICITY [J].
DUMAN, RS ;
HENINGER, GR ;
NESTLER, EJ .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1994, 182 (12) :692-700
[10]   ALTERATION OF SEROTONIN RELEASE IN THE GUINEA-PIG ORBITOFRONTAL CORTEX BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS - RELEVANCE TO TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER [J].
ELMANSARI, M ;
BOUCHARD, C ;
BLIER, P .
NEUROPSYCHOPHARMACOLOGY, 1995, 13 (02) :117-127